

Epoxygenated Fatty Acids and Soluble Epoxide Hydrolase Inhibition: Novel Mediators of Pain Reduction[†]

Karen Wagner,[§] Bora Inceoglu,[§] Sarjeet S. Gill,[#] and Bruce D. Hammock^{*,§}

[§]Department of Entomology and University of California Davis Cancer Center, University of California—Davis, Davis, California 95616, United States

[#]Department of Cell Biology and Neuroscience, University of California—Riverside, Riverside, California 92521, United States

ABSTRACT: The soluble epoxide hydrolase (sEH) enzyme was discovered while investigating the metabolism of xenobiotic compounds in the Casida laboratory. However, an endogenous role of sEH is to regulate the levels of a group of potent bioactive lipids, epoxygenated fatty acids (EFAs), that have pleiotropic biological activities. The EFAs, in particular the arachidonic acid derived epoxy eicosatrienoic acids (EETs), are established autocrine and paracrine messengers. The most recently discovered outcome of inhibition of sEH and increased EFAs is their effects on the sensory system and in particular their ability to reduce pain. The inhibitors of sEH block both inflammatory and neuropathic pain. Elevation of EFAs, in both the central and peripheral nervous systems, blocks pain. Several laboratories have now published a number of potential mechanisms of action for the pain-reducing effects of EFAs. This paper provides a brief history of the discovery of the sEH enzyme and argues that inhibitors of sEH through several independent mechanisms display pain-reducing effects.

KEYWORDS: pain, inflammatory pain, diabetic neuropathic pain, hyperalgesia, nociception, EETs, epoxygenated fatty acids, soluble epoxide hydrolase, somatostatin

As illustrated by this collection of papers, the laboratory of John Casida is renowned for the number of new fields that have emerged from the basement of Wellman Hall at the University of California—Berkeley. One could accuse the laboratory of being a nebula for the birthplace of new ideas in toxicology. There are probably many reasons for this phenomenon. Certainly one reason is John Casida's approach of scouring the literature for interesting problems and then presenting an interesting question to a new student or postdoctoral fellow. We see this approach repeated many times with fields including the ryanodine story, GABA agonists, neonicotinoids, pyrethroids, absinthine mechanism, insecticide resistance, cytochrome P450, and other areas. A second reason is John's willingness to give scientists in his laboratory a free reign to approach a problem in their own way. Certainly a major reason is John's insatiable curiosity. He certainly does not jump from one field to another, rather he moves from one scientific strength to another strength where an established approach is applied to new problems and then these problems stimulate the development of new approaches and techniques. Many scientists are lacking either the courage or skill to move on to new things, but John Casida has a career brimming with courage, skill, and creativity. Of course, his students and colleagues wonder why he deserts such lucrative fields after a period of years to move on to more exciting areas. Is he giving his protégées a new field of endeavor, or is John just so very curious that he must try something new? As he commonly says, the most interesting project he has ever worked on is "the next project".

Sarjeet Gill and I (B.D.H.) arrived in John's laboratory as graduate students on the same day, and neither of us had bothered to warn him that we were coming to work for him. Sarjeet may have gotten more encouragement. However, with me, John was exceptionally nice, and then he explained that "graduate students were not

cost effective, space effective, or time effective" and went on to say that he was "limited by resources, space, and time." Of course, neither of us left John's laboratory, and we shared the low-ceiling room behind Irene next to the housefly room as both office and laboratory. To complicate John's life further, we both had read Carroll Williams' *Scientific American* paper on third-generation pesticides¹ and were determined not only to work with John but also to work on insect juvenile hormone. After several months, John noticed that we both filled out paperwork that he was our major professor and accepted us with some reluctance. After both of us failed at projects including isolating juvenile hormone active compounds from plants, isolating mitochondria from mites, pyrethroid metabolism, and a few other projects, he then suggested that we work on an experimental insecticide from Stauffer Chemical Co. that mimicked insect juvenile hormone and was termed R-20458.

Shortly before Christmas of 1969 the compound was radiolabeled in two positions with tritium,² Sarjeet was assigned to do mammalian metabolism and environmental degradation, whereas I was assigned to synthesize possible metabolites and carry out insect metabolism work. These research boundaries were poorly respected, resulting in collaboration and entertainment that has lasted for 40 years.

Sarjeet found that R-20458 produced a vast array of metabolites both in mammalian liver homogenates and in vivo. As in insects, Sarjeet found that a major mammalian metabolite of R-20458 was from the hydrolytic opening of the 6,7-epoxide to the corresponding diol,³ The surprise was that in contrast to the excellent work

Special Issue: Casida Symposium

Received: July 1, 2010

Revised: September 15, 2010

Accepted: September 22, 2010

Published: October 19, 2010

[†] Part of the Symposium on Pesticide Toxicology in Honor of Professor John Casida. Both S.S.G. and B.D.H. were graduate students with Professor Casida at ECTL 1969–1973 and postgraduate fellows in 1973.

pioneered in John Daley's laboratory at NIH and Gerry Brooks in England,⁴ the enzyme responsible was largely in the 100,000 g soluble fraction of tissue homogenates. Over several years we made multiple attempts to disprove the diol structure, disprove the enzyme's subcellular localization, and disprove that an epoxide hydrolase was involved in its production. When these efforts failed, no objection was raised when a soluble epoxide hydrolase (sEH) was suggested to be involved in the production of one of a very large number of metabolites of R-20458.⁵ For several years after leaving the Casida laboratory we worked on the hypothesis that the soluble epoxide hydrolase had been overlooked because the enzyme favored trisubstituted lipophilic substrates including terpene oxides such as farnesol 10,11 or squalene 2,3 epoxides. However, Susanne Mumby prepared a series of epoxides similar to R-20458 to find that the enzyme was very active both on monosubstituted epoxides and on *cis*- and *trans*-1,2-disubstituted epoxides. The resulting paper may have set a record for the number of journals that rejected it before Elvins Spencer stated that young faculty "deserve the freedom to make fools of themselves" and accepted the paper with three negative reviews.⁶ This surprising substrate selectivity quickly led to a study explaining why other laboratories had missed the enzyme⁷ and a report by us⁸ that the enzyme rapidly turned over epoxy fatty acids. The properties of the enzyme as well as its activity on fatty acids quickly led to the hypothesis that epoxides of arachidonic acid could be important chemical mediators and that the soluble epoxide hydrolase was degrading them just as insect juvenile hormone esterase degraded the insect chemical mediator juvenile hormone. During this period I carried vials of epoxides of arachidonate (epoxyeicosanoids, EETs) and their mimics from the University of California—Riverside around the world, begging people to test them. The general failure to find biological activity in retrospect may have been due to the rapid metabolism of the EETs by the soluble epoxide hydrolase (compounded by a lack of enthusiasm from collaborators). Despite the hypothesis that the epoxide hydrolase and EETs were involved in chemical mediation, funding for work on the enzyme was almost exclusively for its role in xenobiotic metabolism for many years.

Through the years the enzyme was purified, characterized, cloned, and expressed. Also during this period there were a number of attempts to design effective inhibitors, but none of these compounds was sufficiently stable *in vivo* to provide convincing evidence of a role of the soluble epoxide hydrolase in chemical mediation. When the mechanism of catalysis of the enzyme was determined to be a two-step process like all known α/β -hydrolase fold enzymes,⁹ Morisseau et al. were able to design ureas, carbamates, and amides that were potent transition state mimics of the enzyme.¹⁰ These inhibitors of the sEH, or sEHIs, were both potent and stable enough that they could be used to demonstrate unequivocally a role for the soluble epoxide hydrolase *in vivo* in the hydrolysis of lipid epoxide chemical mediators. Several of the sEHIs commonly used in animal models are shown in Figure 1. In parallel, over this period, evidence was building that arachidonic acid epoxides and other fatty acid epoxides could have endogenous roles in chemical mediation. Thus, samples of epoxide hydrolase inhibitors joined samples of EETs being delivered to laboratories around the world. An early collaboration with Deanna Kroetz resulted in a demonstration of blood pressure lowering in spontaneously hypertensive rats,¹¹ but it was the recruitment of John Imig¹² and later Rudi Busse¹³ as well respected cardiovascular scientists in the United States and Europe when the effectiveness of soluble epoxide hydrolase inhibitors and thus EETs became more widely recognized in cardiovascular biology.^{14–16}

Producing sEH inhibitors that were of increased potency as sEH inhibitors proved to be easier than making compounds that

In vitro potency (nM)




Figure 1. sEHIs commonly used in animal models. Accepted abbreviation and potency are indicated with structures. In vitro potency (IC_{50}) was determined using the fluorescent substrate CMNPC, an α -cyano-carbonate, on baculovirus-expressed and affinity-purified recombinant human sEH.

were easy to administer to animals and gave good pharmacokinetics. Much of the inspiration in this effort was drawn from agricultural chemistry.⁴ However, there have been a number of studies through the years to develop such compounds.^{17,18} Figure 1 shows a sequence of some of the structures from this laboratory that has yielded tools for generating "chemical knock outs" of the sEH catalytic activity. These inhibitors coupled with the wider acceptance of EETs and epoxides of other fatty acids (EFAs) and the wider availability of reagents led more scientists to try these reagents to demonstrate biological activity of EFAs. These biological activities included protection against end organ damage,¹⁹ pulmonary inflammation,²⁰ acute inflammation,²¹ vascular inflammation,²² stroke,²³ heart attack,²⁴ and other biologies. More recently, there seems to be involvement of sEH inhibition in moderating the effects of diabetes²⁵ and atherosclerosis.^{26,27} Several reviews have covered aspects of the physiological events influenced with sEH inhibitors.^{9,12,14,17}

Because sEH inhibitors were found to reduce inflammation in multiple systems, it seemed quite logical to try sEH inhibitors and EETs in inflammatory pain models. It was no surprise when the pain was reduced in multiple systems.^{28,29} Because it was not anticipated that sEH inhibitors would influence neuropathic pain, this biological model was tried as an anticipated negative control. Surprisingly, the compounds were very powerful in reducing even neuropathic pain, and this exciting biological observation is the focus of the novel science reported here.

SOLUBLE EPOXIDE HYDROLASE AND EPOXY FATTY ACIDS

Many classes of lipids are bioactive molecules.³⁰ Likewise, EFAs have pleiotropic biological roles.^{14,19,21,31} Over the past few decades incremental advances in detecting and quantifying these molecules have culminated in a better view of their functionality




Figure 2. Selected free fatty acids and their corresponding EFA metabolites generated by CYP450 monoepoxygenases. Each olefin bond can be epoxidized to yield six regioisomers from DHA, five from EPA, and four from AA.

and their importance in cellular signaling. More importantly, the realization that the soluble epoxide hydrolase (sEH, *EPHX2*) is the major enzyme metabolizing these endogenous EFAs was pivotal to our understanding of their biological roles.³² It was not until at least 15 years later that selective inhibitors of the sEH enabled the ability to modulate their levels *in vivo*.¹⁰ Although the recently described beneficial neurobiological effects are the primary focus of this paper, studies dating back to the early 1980s indicate fundamental roles for EFAs in the central nervous system.³³ Among the multiple actions of EFAs, the pain-reducing effects are most unexpected. EFAs do not fulfill the criteria of neurotransmitters, that is, presynaptic presence, release due to calcium dependent depolarization, and receptors on postsynaptic cells. Furthermore, they are not known ligands of nervous system modulating ion channels. Despite the lack of these properties, they modulate a number of physiological and pathophysiological processes in the nervous system.

Three major classes of enzymes, cyclooxygenase (COX), lipoxigenases (LOX), and cytochrome P450 monoepoxygenases (CYP450), use arachidonic acid (AA) as a substrate, all of which have a number of isoforms producing a plethora of bioactive lipids. Overall, a significant portion of current pharmaceuticals act on the AA cascade,³⁴ making this cascade a traditional target for mitigating pain and inflammation. The sEH is a downstream enzyme in the less well studied CYP450 branch of the AA cascade. In contrast to selective COX inhibitors (coxibs), NSAIDs, and LOX inhibitors that block the production of pro-inflammatory lipid mediators, inhibition of sEH stabilizes and elevates anti-inflammatory and analgesic EFAs. Although this third branch of the AA cascade was first discovered in the 1970s, its importance is not broadly recognized. Currently there are no approved drugs on the market that specifically modulate the activities of the CYP450 epoxygenases, sEH, or their products.

The AA derived EETs have so far been the subject of most investigations concerning EFAs. Nevertheless, epoxygenation of free fatty acids by epoxygenases will yield epoxy fatty acids from linoleic, linolenic, arachidonic, eicosapentaenoic, and docosahexaenoic acids, each with multiple regioisomers (Figure 2). The number of monoepoxy regioisomers formed in these cases depends on the number of olefin bonds in the parent fatty acid. From each regioisomer two possible enantiomers may be produced, resulting in the formation of a multitude of bioactive molecules.^{35,36}

The distribution, quantities, and biological roles of EFAs vary depending on their location and the biological context.¹⁴ Importantly, these lipid epoxides are atypical compared to xenobiotic epoxides because they are neither reactive nor mutagenic.³⁷

The EETs and other EFAs are stable in the absence of enzymes such as the sEH, which degrades them.^{38,39} The sEH enzyme transforms the EETs to their corresponding vicinal diols, the dihydroxyeicosatrienoic acids (DHETs), metabolites deemed mostly inactive.⁴⁰ *In vivo* preparations of endothelial tissue radiolabeled free AA is converted to EETs and further to DHETs.⁴¹ *In vitro*, recombinant sEHs from multiple species convert EETs to DHETs.¹⁰ *In vivo*, inhibitors of sEH prevent the degradation of EETs and increase the plasma EET to DHET ratio.²¹ The substrates of sEH are of course not limited to the EETs but extend to other EFAs. Although most studies cite EETs as the bioactive metabolites stabilized by sEH, this is an oversimplification. Therefore, we will refer to EFAs (which include EETs) for the remainder of this paper.

The sEH enzyme is widely distributed in human tissues.⁴² It is well expressed in the central (CNS) and peripheral nervous systems, including in astrocytes and neurons.^{43,44} The epoxygenases, EETs, sEH, and DHETs are all present in the nervous system.^{45,46} The endogenous levels of the EETs and other EFAs in the CNS are in the low nanomolar range,⁴⁶ and they have exceedingly short half-lives on the order of several seconds.³⁸ Interestingly, the spatial distribution of epoxygenases does not entirely overlap with the presence of sEH. More interestingly, sEH seems to be expressed in a brain region selective manner.^{43,47} Overall, these observations highlight the EFAs' potential role as signaling molecules. It is yet to be determined how these expression patterns relate to functional outcomes.

EFAS AND SEH INHIBITORS BLOCK INFLAMMATORY AND NEUROPATHIC PAIN

Throughout the past few decades the neurobiological effects of EETs have been described, albeit sporadically.^{33,48,49} Here we expand on the novel hypothesis that a major role of EETs and other EFAs is the attenuation of pain. Thus, inhibitors of the sEH by stabilizing EFAs reduce pain through several mechanisms that are not well explored. The fact that few mechanisms are described signals an exciting future for this field.

The possible pain-reducing effects of EFAs were first conceived as a result of targeted metabolomic analysis while we were investigating the anti-inflammatory activity of sEH inhibitors.²¹ These *in vivo* studies demonstrated the sEH inhibitors cause a dramatic reduction in morbidity and mortality in mice treated with lipopolysaccharide (LPS). An increase in epoxide to diol ratios of EFAs supported the mechanism of action of the inhibitors and showed target engagement.²⁸ However, we were surprised that the reduction in the inflammatory eicosanoid prostaglandin E₂ (PGE₂) was far more dramatic than the effects on EFAs. Because PGE₂ causes both pain and inflammation, it was logical to try sEH inhibitors as therapeutics for inflammatory pain.^{28,29} The initial indication that EETs and possibly other EFAs are powerful anti-inflammatory molecules came from observations made by Nakashima et al., who described the antipyretic properties of endogenous epoxygenase metabolites in the brain.⁴⁸ This was further supported by Node et al., who demonstrated a mechanism of action for EETs *in vitro* involving the NFκB pathway.⁵⁰ We then tested the effects of EFAs *in vivo* by chemically inhibiting the sEH.²¹ These *in vivo* studies demonstrated that sEH inhibitors reduce the formation of metabolites of the COX-2 enzyme in liver and plasma, specifically the pro-inflammatory and pain-producing molecule PGE₂.

Our initial work in testing this hypothesis focused on intraplantar injection of a small amount of LPS (10 μg) into one hind paw of rats.²⁹ This pain model was an extension of the mouse sepsis model




Figure 3. EFAs block inflammatory pain. Area under the curve (efficacy vs time) for key EFAs with and without the sEHI AUDA-be (butyl ester) using the Hargreaves thermal hyperalgesia test ($n = 4$ per group) is shown. Control animals did not receive LPS and thus are not inflamed. The LPS group received a single intraplantar injection of LPS ($10 \mu\text{g}$) in one hind paw. All EFAs and sEHI were formulated in Vanicream and administered topically at a dose of 50 mg/kg as described.²⁹ LPS injection dramatically reduces the threshold for pain, decreasing the latency of thermal withdrawal responses; thus, this group has a lower AUC. EFAs of DHA, EPA, and AA were equally efficacious in reducing pain. The sEHI AUDA-butyl ester was also highly efficacious in eliminating inflammatory pain. Co-administration of EETs with sEHI prolonged the efficacy of the EETs and produced an additive effect in reducing pain.

induced by a large dose of LPS (10 mg/kg), in which sEH inhibitors were highly efficacious in reducing PGE_2 and improving the survival of mice.²¹ Intraplantar LPS (Figures 3 and 4) instigates an inflammatory response that elicits a disproportionate sensitivity to normally innocuous stimuli (allodynia) and increased sensitivity to moderately painful stimuli (hyperalgesia).⁵¹ These two types of sensory information are relayed by different types of neurons that are specialized to receive and transmit pain-related information (nociceptors).⁵² Many pain-reducing (antihyperalgesic) compounds including NSAIDs and narcotic analgesics variably affect these two sensory parameters. It is interesting to observe that all sEH inhibitors tested were highly efficacious in the LPS-elicited inflammatory pain model (Figure 4). Importantly, despite being efficacious in pain models, none of the sEHs tested at doses highly effective in inflamed animals changed acute pain thresholds or motor responses of healthy animals.⁵³ This indicates that sEHs do not act like narcotics.

Inhibition of sEH is both antihyperalgesic and antiallodynic in tests measuring thermal and mechanical stimuli separately in the inflamed paw. The time course of the antihyperalgesic effect of sEH inhibition in these experiments demonstrates that pain reduction is both rapid onset and of long duration. Interestingly, therapeutic and prophylactic administrations of sEHs are equally effective in reducing pain, implying the involvement of multiple mechanisms of action in mediating their antihyperalgesic effects.

The design, synthesis, and characterization of chemically different, potent, and bioavailable sEH inhibitors over the past several years allowed us to test and support the hypothesis that sEHI induced pain reduction is not a compound-related observation but is due to inhibition of the sEH. Consistent with this hypothesis, not only EETs but also other EFAs of DHA and EPA origin are highly efficacious (Figure 3) in reducing the hyperalgesia elicited by LPS.²⁹ Furthermore, co-administration of EETs with a sEHI results in an additive increase in antihyperalgesia. This result supports the argument that




Figure 4. sEHs block inflammatory pain. The line graph shows the elimination of inflammatory pain by TPAU using the Hargreaves thermal hyperalgesia test ($n = 4$ per group). The LPS + vehicle group received a single intraplantar injection of LPS ($10 \mu\text{g}$) in one hind paw following baseline measurements. Immediately thereafter, TPAU formulated in PEG400 was administered subcutaneously at the doses indicated. LPS injection over time dramatically increased pain from baseline thermal withdrawal latency responses. TPAU was effective in a dose-dependent manner. TPAU at a 1 mg/kg dose was sufficient to completely eliminate inflammatory pain with the dotted line showing the control thermal withdrawal latency.

sEHs stabilize EETs and other EFAs and that the observed biological effects are produced by these bioactive lipid metabolites.

Our original hypothesis was that sEHs reduce inflammatory pain by reducing painful mediators of inflammation. An unexpected observation came about when we used a model of diabetes-induced neuropathic pain (DNP) as a negative control while testing sEHs. A number of sEH inhibitors displayed impressive pain-reducing effects in this model, one of which is reported.⁵³ Until this observation, there was no indication that the pain-reducing effects of EFAs or sEHI would extend beyond inflammatory pain. In this model a single injection of the microbial toxin streptozocin primarily kills pancreatic β -islet cells to generate a hyperglycemic state and measurable allodynia as soon as 2 days after toxin administration.⁵⁴ In the DNP model NSAIDs or selective coxibs are not efficacious, although debate about the inflammatory nature of this model is ongoing. A key part of the etiology of the DNP is hyperglycemia.^{55,56} Thus, it will be important to test if inhibition of sEH reduces this neuropathy by way of regulating hyperglycemia or insulin signaling, in particular given a recent paper suggesting that sEH may be involved in regulating insulin secretion.²⁵ Overall, inhibition of sEH seems to have a broader efficacy profile than that of coxibs and NSAIDs. Notably, co-administration of sEHI with either coxibs or NSAIDs results in a synergistic reduction in plasma PGE_2 during LPS-elicited inflammation.²⁸ Thus, sEHs not only are efficacious as standalone analgesics but also offer a number of advantages in making the coxibs and NSAIDs safer and more efficacious, such as restoring the plasma prostacyclin to thromboxane ratio of rofecoxib-treated mice.²⁸

PERIPHERAL AND CENTRAL NERVOUS SYSTEMS ARE BOTH AFFECTED BY SEHI

The powerful pain-reducing effects of EFAs and sEHI in inflammatory and neuropathic pain models naturally brings up a fundamental question in regard to their site of action. The peripheral nervous system (PNS) activity of sEH inhibitors is

clearly apparent via local administration of very low amounts of sEHI attenuating both thermal and mechanical pain. To test if inhibition of sEH in the CNS would also attenuate pain, we administered the sEHI, AEPU, into the spinal cord in a carrageenan-elicited rat pain model.⁵³ Intraplantar carrageenan, much like LPS, leads to an intense and sustained pain state in which animals display both hyperalgesia and allodynia, although these effects are local and are largely limited to the carrageenan-administered paw. The response thresholds for mildly painful and innocuous stimuli are drastically reduced (about 5-fold) in the carrageenan-administered paw. The sEHIs effectively attenuate carrageenan-elicited pain in a dose-dependent manner whether administered by dermal or intraspinal routes.⁵³ Interestingly, thermal hyperalgesia was more favorably reduced than mechanical allodynia in these experiments, implying selective effects of inhibition of sEH in the CNS.

LPS- or carrageenan-mediated inflammation in the hind paw of the rat generates locally mediated hyperalgesia and allodynia. However, this changes after a period of continuous transmission of pain signals. A barrage of nociceptor cell firings from the paw (periphery area) to the spinal cord and the brain (central area) leads to "central sensitization", in which neurons in the spinal cord and brain (CNS) become more responsive to signals that are smaller in magnitude. The etiology of this phenomenon is beyond the scope of this paper, although one component of central sensitization, the transcriptional plasticity of genes that produce proinflammatory molecules, is worth mentioning. In the LPS-elicited inflammatory pain model LPS injection to the hind paw leads to up-regulation of the cyclooxygenase-2 message and protein both locally and in the spinal cord and brain, which results in increased production of pro-inflammatory prostanoids, particularly PGE₂.⁵⁷ The spinally produced PGE₂ generates further pain signaling by directly acting on cells expressing E-prostanoid receptors and independently makes cells more responsive to incoming signals from the periphery.⁵⁸ This process amplifies the pain signals and results in increased perceived pain. Some selective inhibitors of COX-2 penetrate through the blood-brain barrier⁵⁹ and therefore reduce the production of PGE₂ both in the periphery and in the spinal cord.⁶⁰ Interestingly, both EFAs and sEHI act to suppress the induction of the COX-2 message and protein. The first in vivo indication of this characteristic action was the observation that sEHIs had effects consistent with anti-inflammatory activity in the mouse sepsis model.²¹ In this model sEHI reduced the plasma levels of PGE₂, which was through suppression of the induction of COX-2 protein in the liver. When we tested if this held true in the spinal cord, we found that sEHIs were highly effective in suppressing LPS-elicited up-regulation of COX-2 (27-fold) in the spinal cord.⁵³ Thus, peripherally administered sEHIs directly modulated CNS transcriptional plasticity. Given that Node et al. demonstrated in vitro that EETs prevent the nuclear translocation of NFκB, it is likely that sEHIs suppress spinal COX-2 through this mechanism.⁵⁰

Overall, the systemic versus intraspinal efficacies of sEHI seem to be at least 100-fold different in favor of intraspinal sEHI. Furthermore, all sEHIs tested so far penetrate through the blood-brain barrier. For several compounds brain concentrations were about 10% of blood concentrations. These sEHIs were detected in quantities in the brain well above their in vitro potency (IC₅₀) on the affinity-purified recombinant rat sEH enzyme. These observations strongly suggest that sEHI are both peripherally and centrally acting pain-reducing agents. Further support toward the central

mechanism of action of EETs and thus sEHI comes from two recent studies to be discussed later.^{61,62}

■ MULTIPLE MECHANISMS ARE IN PLAY FOR SEHI-MEDIATED ANALGESIA

Suppression of Spinal COX-2. The suppression of COX-2 gene expression in the CNS by sEHI is certainly an interesting part of the mechanism of action of sEH inhibitors. The time course of spinal COX-2 suppression described earlier was surprisingly not correlated with the observed decreases in pain-related behavior in inflamed rats. This inconsistency led us to hypothesize that suppression of spinal or peripheral COX-2 induction may not be the sole mechanism of action for sEHIs. Consistent with this idea, in the DNP model sEHIs show considerable bioefficacy, whereas even selective coxibs that penetrate through the blood-brain barrier do not reduce DNP. Therefore, it is unlikely that sEHIs reduce DNP solely by suppressing spinal COX-2 up-regulation. The extent of the spinal up-regulation of COX-2 in DNP is in fact very minor compared to intraplantar LPS-elicited up-regulation of spinal COX-2 (3- vs 27-fold).^{53,63}

Release of Endogenous Analgesic Peptides. Recently, in the rat, Terashvili et al. demonstrated that direct administration of EETs into the ventrolateral periaqueductal gray (vlPAG) of the brain leads to decreased acute pain responses.⁶¹ This analgesic effect seems to be mediated through the enhanced release of β-endorphin and met-enkephalin, two important endogenous opioid peptides. These are highly valuable observations given that the authors monitored acute pain responses in the absence of an underlying painful state. In our experiments, using very potent sEHIs (IC₅₀ in the low nM range), we have not encountered effects on acute pain thresholds in the absence of induced pain even when sEHIs were administered at doses at least 10 times higher than was required to reduce existing pain. These doses result in plasma sEHI concentrations that are many times (100–1000) above their in vitro IC₅₀, and they are found in the brain tissue at levels at least 10 times above their in vitro IC₅₀. It seems that the different thermal and mechanical threshold pain assays utilized by Terashvili et al. and our laboratory are the key to the differences between observations. In future studies it will be important to establish the relationship between the tissue inhibitor level, the tissue EFA level, and bioefficacy. Nevertheless, the findings of Terashvili et al. support the hypothesis that EETs are analgesic molecules that act on the CNS.⁶¹ This exciting mechanism of action was more recently supported by the work of Conroy et al., who demonstrated that genetic deletion of brain CYP450 reductase or pharmacological inhibition of CYP450 epoxygenases in mice and rats abolished morphine analgesia.⁶² These authors suggest that epoxygenases in the vlPAG region are required for the analgesic actions of morphine and endogenous opioid peptides that stimulate and activate the descending analgesic pathway, which is known to inhibit spinal nociception.⁶⁴ Given that EETs are one of the important products of the CYP450 epoxygenases, it is conceivable that yet another mechanism of action responsible for our observations is through activation of the descending analgesic pathway.

Over 25 years ago EET regioisomers were found to increase the release of somatostatin peptide in vitro.³³ EETs are reported secretagogues for modulatory peptides including somatostatin in the hypothalamus and have possible action on insulin and pituitary adrenocorticotrophic hormone (ACTH) secretions.^{65,66} Somatostatin in the brain and the spinal cord⁶⁷ has direct pain-reducing effects.⁶⁸ Peptide neurotransmitters in the CNS are usually found in the same secretory vesicles.^{69,70} Thus, release of somatostatin would




Figure 5. Inhibition of sEH dramatically elevates spinal somatostatin mRNA expression. Male rats received a single intraplantar injection of 10 μ g of LPS in one hind paw. The sEHI group received TPAU (10 mg/kg) subcutaneously, dissolved in PEG400, whereas the LPS group received PEG400 only. Another group of rats received intraplantar saline and PEG400 but not LPS or TPAU. This third group was used as calibrators for the quantitative RT-PCR. Spinal cords were extracted at indicated times, and mRNAs were isolated and subjected to qRT-PCR using GAPDH as the endogenous control as described.⁵³ Data are expressed as mean \pm sem, $n = 4$ per group for each time point.

simultaneously occur with the release of endogenous opioid peptides. EETs may induce the release of opioid peptides in the CNS as argued by Terashvili et al., which would be consistent with somatostatin release and points to another possible mechanism of action of the EETs.⁶¹ While we were assessing the spinal COX-2 transcriptional response to sEH inhibition, we used the somatostatin mRNA as a biomarker of inflammation-driven increase in cAMP levels.⁵³ Somatostatin expression is highly responsive to intracellular cAMP levels and is increased by cAMP or inflammation.⁷¹ However, inhibition of sEH mediated a drastic further increase in the transcription of somatostatin mRNA over that produced by inflammation (Figure 5). Altogether, the observations from Capdevila et al.¹⁹ demonstrating the direct release of somatostatin peptide and from our laboratory demonstrating a drastic increase in the mRNA levels indicate that somatostatin secretion is potentially another mechanism responsible for the analgesic effects of EETs and sEHs.

Modulation of CNS Neurohormone Synthesis. In an effort to understand the mechanism(s) of action of EETs, we used a routine screening approach aimed at identifying potential receptors for EETs. This screening yielded a number of interesting and previously not known potential target receptors.⁷² Among these receptors EETs had a striking concentration-dependent and regioisomer-selective effect on the peripheral benzodiazepine receptor renamed TSPO.⁷³ This protein is an intramitochondrial transporter for cholesterol that translocates cholesterol molecules from the outer to the inner mitochondrial membrane.⁷⁴ This translocation is a required and rate-limiting step for all steroid biosyntheses.⁷⁵ The EETs displaced a high-affinity radioligand, [3H]PK11195, from the TSPO. On the basis of the known function of TSPO in steroid synthesis, we tested if blocking general steroid synthesis at a downstream step from TSPO would affect the efficacy of sEHI. It was surprising to demonstrate that inhibition of steroid synthesis would produce full antagonism to the analgesic effects of sEHI. These findings strongly suggest the involvement of steroid synthesis, in particular, CNS steroid synthesis, in the mechanism of action of EETs and sEHs. In parallel to our results,

Wang et al. proposed that EETs enhance the expression of another key protein in the steroid synthesis pathway, the steroidogenic acute regulatory protein (StARD1), which shuttles cholesterol to TP50.⁷⁶ We tested if administration of sEHI modulated spinal levels of the StARD1 mRNA. Expectedly, spinal StARD1 was significantly induced in the presence of stabilized EETs or sEHI in rats treated with intraplantar LPS. Given the positive interaction between StARD1 and intracellular cAMP, we tested if spinal administration of a cAMP analogue together with a EET or sEHI would change StARD1 expression. Administration of inhibitors of sEH and EETs was ineffective in increasing StARD1 expression by themselves but did so when co-administered with 8-bromo cAMP both in the brain and in the spinal cord. Future studies will address the possibility of synergism of combined elevated cAMP and sEHI treatment. Regardless, these observations indicate the presence of another unique mechanism independent from those already reported.

The case for pain-reducing effects of EFAs and sEHs now is well supported through observations from a number of laboratories. These effects seem sufficiently different from all known pain-reducing agents that the sEHs as well as EFAs and their mimics can be placed in a class of their own. Specifically, sEHs reduce the levels of pro-inflammatory lipid mediators during inflammation but do not inhibit either of the COX isozymes. sEHs suppress the induction of COX-2 transcription but do not share other properties with steroidal anti-inflammatory drugs. Finally, sEHs are effective in models of pain for which NSAIDs, coxibs, and steroidal anti-inflammatory drugs fail. It is also clear that the pain-reducing effects are governed by several independent mechanisms. So far, work in this area has been descriptive because the effects are novel and unexpected. Future work is bound to yield even more interesting and unexpected results. Of particular interest will be the use of EFAs, EFA mimics, and antagonists as well as sEHs to probe the fundamental mechanisms of pain detection and suppression. Regardless, the mechanisms of action of these effects must be investigated to learn how, when, and where EFAs and sEHs modulate physiological events. On the other hand, it is possible that this discovery can be relatively rapidly moved toward clinical testing. Neuropathic pain, in particular, and also inflammatory pain associated with comorbidities both remain unmet therapeutic needs. Despite the importance of pain, it is interesting that the rate of discovery for new molecular entities and drugs to treat pain is not increasing.⁷⁷ Inhibition of sEH appears to be a viable approach for treating inflammatory and neuropathic pain. Thus, work initiated in the Casida laboratory 40 years ago on xenobiotic metabolism and insect metamorphosis may by a circuitous path lead to the treatment of such maladies as diabetic neuropathic pain.

■ AUTHOR INFORMATION

Corresponding Author

*Postal address: Department of Entomology, University of California—Davis, One Shields Ave., Davis, CA 95616. Phone: (530) 751-7519. Fax: (530) 752-1537. E-mail: bdhammock@ucdavis.edu.

Funding Sources

Support for this work was provided by NIEHS Grant R01 ES002710, NIEHS Superfund Basic Research Program P42 ES004699, and NIH/NHLBI R01 HL059699 to B.D.H. and NIEHS T32ES007059 to K.M.W. B.D.H. is a George and Judy Marcus Senior Fellow of the American Asthma Foundation.

REFERENCES

- (1) Williams, C. M. Third-generation pesticides. *Sci. Am.* **1967**, *217* (1), 13–17.
- (2) Kamimura, H.; Hammock, B. D.; Yamamoto, I.; Casida, J. E. Potent juvenile hormone mimic, 1-(4'-ethylphenoxy)-6,7-epoxy-3,7-dimethyl-2-octene, labeled with tritium in either the ethylphenyl- or geranyl-derived moiety. *J. Agric. Food Chem.* **1972**, *20* (2), 439–442.
- (3) Gill, S. S.; Hammock, B. D.; Yamamoto, I.; Casida, J. E. *Preliminary Chromatographic Studies on the Metabolites and Photodecomposition Products of the Juvenoid 1-(4'-Ethylphenoxy)-6,7-epoxy-3,7-dimethyl-2-octene*; Academic Press: New York, 1972.
- (4) Morisseau, C.; Hammock, B. D. Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical. *Pest Manag. Sci.* **2008**, *64*, 594–609.
- (5) Gill, S. S.; Hammock, B. D.; Casida, J. E. Mammalian metabolism and environmental degradation of the juvenoid 1-(4'-ethylphenoxy)-3,7-dimethyl-6,7-epoxy-*trans*-2-octene and related compounds. *J. Agric. Food Chem.* **1974**, *22* (3), 386–395.
- (6) Mumby, S. M.; Hammock, B. D. Substrate selectivity and stereochemistry of enzymatic epoxide hydration in the soluble fraction of mouse liver. *Pestic. Biochem. Physiol.* **1979**, *11* (1–3), 275–284.
- (7) Ota, K.; Hammock, B. D. Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. *Science* **1980**, *207* (4438), 1479–1481.
- (8) Gill, S. S.; Hammock, B. D. Hydration of *cis*- and *trans*-epoxymethyl stearates by the cytosolic epoxide hydrase of mouse liver. *Biochem. Biophys. Res. Commun.* **1979**, *89* (3), 965–971.
- (9) Morisseau, C.; Hammock, B. D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. *Annu. Rev. Pharmacol. Toxicol.* **2005**, *45*, 311–333.
- (10) Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96* (16), 8849–8854.
- (11) Yu, Z.; Xu, F.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circ. Res.* **2000**, *87* (11), 992–998.
- (12) Imig, J. D.; Zhao, X.; Capdevila, J. H.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension* **2002**, *39* (2 Part 2), 690–694.
- (13) Jung, O.; Brandes, R. P.; Kim, I. H.; Schweda, F.; Schmidt, R.; Hammock, B. D.; Busse, R.; Fleming, I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. *Hypertension* **2005**, *45* (4), 759–765.
- (14) Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat. Rev. Drug Discov.* **2009**, *8* (10), 794–805.
- (15) Imig, J. D.; Zhao, X.; Zaharis, C. Z.; Olearczyk, J. J.; Pollock, D. M.; Newman, J. W.; Kim, I. H.; Watanabe, T.; Hammock, B. D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. *Hypertension* **2005**, *46* (4), 975–981.
- (16) Imig, J. D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. *Am. J. Physiol. Renal Physiol.* **2005**, *289* (3), F496–F503.
- (17) Shen, H. C. Soluble epoxide hydrolase inhibitors: a patent review. *Expert Opin. Ther. Pat.* **2010**, *20* (7), 941–956.
- (18) Tsai, H. J.; Hwang, S. H.; Morisseau, C.; Yang, J.; Jones, P. D.; Kasagami, T.; Kim, I. H.; Hammock, B. D. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. *Eur. J. Pharm. Sci.* **2010**, *40* (3), 222–238.
- (19) Zhao, X.; Yamamoto, T.; Newman, J. W.; Kim, I. H.; Watanabe, T.; Hammock, B. D.; Stewart, J.; Pollock, J. S.; Pollock, D. M.; Imig, J. D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *J. Am. Soc. Nephrol.* **2004**, *15* (5), 1244–1253.
- (20) Smith, K. R.; Pinkerton, K. E.; Watanabe, T.; Pedersen, T. L.; Ma, S. J.; Hammock, B. D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102* (6), 2186–2191.
- (21) Schmelzer, K. R.; Kubala, L.; Newman, J. W.; Kim, I. H.; Eiserich, J. P.; Hammock, B. D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102* (28), 9772–9777.
- (22) Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T. S.; Fang, X.; Zhu, Y.; Spector, A. A.; Gill, S.; Morisseau, C.; Hammock, B. D.; Shyy, J. Y. The antiinflammatory effect of laminar flow: the role of PPAR γ , epoxyeicosatrienoic acids, and soluble epoxide hydrolase. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102* (46), 16747–16752.
- (23) Dorrance, A. M.; Rupp, N.; Pollock, D. M.; Newman, J. W.; Hammock, B. D.; Imig, J. D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. *J. Cardiovasc. Pharmacol.* **2005**, *46* (6), 842–848.
- (24) Seubert, J. M.; Sinal, C. J.; Graves, J.; DeGraff, L. M.; Bradbury, J. A.; Lee, C. R.; Goralski, K.; Carey, M. A.; Luria, A.; Newman, J. W.; Hammock, B. D.; Falck, J. R.; Roberts, H.; Rockman, H. A.; Murphy, E.; Zeldin, D. C. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. *Circ. Res.* **2006**, *99* (4), 442–450.
- (25) Luo, P.; Chang, H. H.; Zhou, Y.; Zhang, S.; Hwang, S. H.; Morisseau, C.; Wang, C. Y.; Inscho, E. W.; Hammock, B. D.; Wang, M. H. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. *J. Pharmacol. Exp. Ther.* **2010**, *334* (2), 430–438.
- (26) Ulu, A.; Davis, B. B.; Tsai, H. J.; Kim, I. H.; Morisseau, C.; Inceoglu, B.; Fiehn, O.; Hammock, B. D.; Weiss, R. H. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. *J. Cardiovasc. Pharmacol.* **2008**, *52* (4), 314–323.
- (27) Wang, Y. X.; Ulu, A.; Zhang, L. N.; Hammock, B. Soluble epoxide hydrolase in atherosclerosis. *Curr. Atheroscler. Rep.* **2010**, *12* (3), 174–183.
- (28) Schmelzer, K. R.; Inceoglu, B.; Kubala, L.; Kim, I. H.; Jinks, S. L.; Eiserich, J. P.; Hammock, B. D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103* (37), 13646–13651.
- (29) Inceoglu, B.; Jinks, S. L.; Schmelzer, K. R.; Waite, T.; Kim, I. H.; Hammock, B. D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. *Life Sci.* **2006**, *79* (24), 2311–2319.
- (30) Hla, T. Genomic insights into mediator lipidomics. *Prostaglandins Other Lipid Mediators* **2005**, *77* (1–4), 197–209.
- (31) Smith, A. D.; Dorrance, A. M. Arachidonic acid induces augmented vasoconstriction via cyclooxygenase 1 in the aorta from rats fed a high-fat diet. *Prostaglandins, Leukotrienes Essent. Fatty Acids* **2006**, *75* (1), 43–49.
- (32) Chacos, N.; Capdevila, J.; Falck, J. R.; Manna, S.; Martin-Wixtrom, C.; Gill, S. S.; Hammock, B. D.; Estabrook, R. W. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. *Arch. Biochem. Biophys.* **1983**, *223* (2), 639–648.
- (33) Capdevila, J.; Chacos, N.; Falck, J. R.; Manna, S.; Negro-Vilar, A.; Ojeda, S. R. Novel hypothalamic arachidonate products stimulate somatostatin release from the median eminence. *Endocrinology* **1983**, *113* (1), 421–423.
- (34) Lednicer, D. *New Drug Discovery and Development*; Wiley-Interscience: Hoboken, NJ, 2007; p xii, 190 pp.
- (35) Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. *J. Lipid Res.* **2000**, *41* (2), 163–181.
- (36) Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. *J. Lipid Res.* **2009**, *50* (Suppl.), S52–S56.

- (37) Chiamvimonvat, N.; Ho, C. M.; Tsai, H. J.; Hammock, B. D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. *J. Cardiovasc. Pharmacol.* **2007**, *50* (3), 225–237.
- (38) Spector, A. A.; Norris, A. W. Action of epoxyeicosatrienoic acids on cellular function. *Am. J. Physiol. Cell Physiol.* **2007**, *292* (3), C996–C1012.
- (39) Fang, X.; Kaduce, T. L.; Weintraub, N. L.; Harmon, S.; Teesch, L. M.; Morisseau, C.; Thompson, D. A.; Hammock, B. D.; Spector, A. A. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. *J. Biol. Chem.* **2001**, *276* (18), 14867–14874.
- (40) Zeldin, D. C. Epoxygenase pathways of arachidonic acid metabolism. *J. Biol. Chem.* **2001**, *276* (39), 36059–36062.
- (41) Fang, X.; Kaduce, T. L.; Weintraub, N. L.; Spector, A. A. Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. *Prostaglandins, Leukotrienes Essent. Fatty Acids* **1997**, *57* (4–5), 367–371.
- (42) Enayetallah, A. E.; French, R. A.; Thibodeau, M. S.; Grant, D. F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. *J. Histochem. Cytochem.* **2004**, *52* (4), 447–454.
- (43) Bianco, R. A.; Agassandian, K.; Cassell, M. D.; Spector, A. A.; Sigmund, C. D. Characterization of transgenic mice with neuron-specific expression of soluble epoxide hydrolase. *Brain Res.* **2009**, *1291*, 60–72.
- (44) Marowsky, A.; Burgener, J.; Falck, J. R.; Fritschy, J. M.; Arand, M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. *Neuroscience* **2009**, *163* (2), 646–661.
- (45) Amruthesh, S. C.; Falck, J. R.; Ellis, E. F. Brain synthesis and cerebrovascular action of epoxyeicosatrienoic acid. *J. Neurochem.* **1992**, *58* (2), 503–510.
- (46) Buczynski, M. W.; Svensson, C. I.; Dumlao, D. S.; Fitzsimmons, B. L.; Shim, J. H.; Scherbert, T. J.; Jacobsen, F. E.; Hua, X. Y.; Yaksh, T. L.; Dennis, E. A. Inflammatory hyperalgesia induces essential bioactive lipid production in the spinal cord. *J. Neurochem.* **2010**, *114* (4), 981–993.
- (47) Zhang, W.; Koerner, I. P.; Noppens, R.; Grafe, M.; Tsai, H. J.; Morisseau, C.; Luria, A.; Hammock, B. D.; Falck, J. R.; Alkayed, N. J. Soluble epoxide hydrolase: a novel therapeutic target in stroke. *J. Cereb. Blood Flow Metab.* **2007**, *27* (12), 1931–1940.
- (48) Nakashima, T.; Harada, Y.; Miyata, S.; Kiyohara, T. Inhibitors of cytochrome P-450 augment fever induced by interleukin-1 β . *Am. J. Physiol.* **1996**, *271* (5 Part 2), R1274–R1279.
- (49) Kozak, W.; Kluger, M. J.; Tesfaigzi, J.; Kozak, A.; Mayfield, K. P.; Wachulec, M.; Dokladny, K. Molecular mechanisms of fever and endogenous antipyresis. *Ann. N.Y. Acad. Sci.* **2000**, *917*, 121–134.
- (50) Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Anti-inflammatory properties of cytochrome P450 epoxyeicosatrienoic acid-derived eicosanoids. *Science* **1999**, *285* (5431), 1276–1279.
- (51) Kanaan, S. A.; Saade, N. E.; Haddad, J. J.; Abdelnoor, A. M.; Atweh, S. F.; Jabbur, S. J.; Safieh-Garabedian, B. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. *Pain* **1996**, *66* (2–3), 373–379.
- (52) Julius, D.; Basbaum, A. I. Molecular mechanisms of nociception. *Nature* **2001**, *413* (6852), 203–210.
- (53) Inceoglu, B.; Jinks, S. L.; Ulu, A.; Hegedus, C. M.; Georgi, K.; Schmelzer, K. R.; Wagner, K.; Jones, P. D.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105* (48), 18901–18906.
- (54) Ahlgren, S. C.; Levine, J. D. Mechanical hyperalgesia in streptozotocin-diabetic rats. *Neuroscience* **1993**, *52* (4), 1049–1055.
- (55) Calcutt, N. A.; David, T. Potential mechanisms of neuropathic pain in diabetes. In *International Review of Neurobiology*; Academic Press: San Diego, CA, 2002; Vol. 50, pp 205–228.
- (56) Edwards, J. L.; Vincent, A. M.; Cheng, H. T.; Feldman, E. L. Diabetic neuropathy: mechanisms to management. *Pharmacol. Ther.* **2008**, *120* (1), 1–34.
- (57) Bingham, S.; Beswick, P. J.; Blum, D. E.; Gray, N. M.; Chessell, I. P. The role of the cyclooxygenase pathway in nociception and pain. *Sem. Cell. Dev. Biol.* **2006**, *17* (5), 544–554.
- (58) Zeilhofer, H. U. Prostanoids in nociception and pain. *Biochem. Pharmacol.* **2007**, *73* (2), 165–174.
- (59) Dembo, G.; Park, S. B.; Kharasch, E. D. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. *Anesthesiology* **2005**, *102* (2), 409–415.
- (60) Zeilhofer, H. U.; Brune, K. Analgesic strategies beyond the inhibition of cyclooxygenases. *Trends Pharmacol. Sci.* **2006**, *27* (9), 467–474.
- (61) Terashvili, M.; Tseng, L. F.; Wu, H. E.; Narayanan, J.; Hart, L. M.; Falck, J. R.; Pratt, P. F.; Harder, D. R. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of β -endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray. *J. Pharmacol. Exp. Ther.* **2008**, *326* (2), 614–622.
- (62) Conroy, J. L.; Fang, C.; Gu, J.; Zeitlin, S. O.; Yang, W.; Yang, J.; VanAlstine, M. A.; Nalwalk, J. W.; Albrecht, P. J.; Mazurkiewicz, J. E.; Snyder-Keller, A.; Shan, Z.; Zhang, S.-Z.; Wentland, M. P.; Behr, M.; Knapp, B. I.; Bidlack, J. M.; Zuiderveld, O. P.; Leurs, R.; Ding, X.; Hough, L. B. Opioids activate brain analgesic circuits through cytochrome P450/epoxyeicosatrienoic acid signaling. *Nat. Neurosci.* **2010**, *13* (3), 284–286.
- (63) Freshwater, J. D.; Svensson, C. I.; Malmberg, A. B.; Calcutt, N. A. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. *Diabetes* **2002**, *51* (7), 2249–2255.
- (64) Basbaum, A. I.; Clanton, C. H.; Fields, H. L. Opiate and stimulus-produced analgesia: functional anatomy of a medullospinal pathway. *Proc. Natl. Acad. Sci. U.S.A.* **1976**, *73* (12), 4685–4688.
- (65) Junier, M. P.; Dray, F.; Blair, I.; Capdevila, J.; Dishman, E.; Falck, J. R.; Ojeda, S. R. Epoxygenase products of arachidonic acid are endogenous constituents of the hypothalamus involved in D2 receptor-mediated, dopamine-induced release of somatostatin. *Endocrinology* **1990**, *126* (3), 1534–1540.
- (66) Capdevila, J. H.; Falck, J. R. Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. *Prostaglandins Other Lipid Mediators* **2000**, *62* (3), 271–292.
- (67) Chapman, V.; Dickenson, A. H. The effects of sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord. *Neuropeptides* **1992**, *23* (3), 147–152.
- (68) Carlton, S. M.; Du, J.; Davidson, E.; Zhou, S.; Coggeshall, R. E. Somatostatin receptors on peripheral primary afferent terminals: inhibition of sensitized nociceptors. *Pain* **2001**, *90* (3), 233–244.
- (69) Mains, R. E.; Eipper, B. A. The tissue-specific processing of Pro-ACTH/endorphin recent advances and unsolved problems. *Trends Endocrinol. Metab.* **1990**, *1* (8), 388–394.
- (70) Rouille, Y.; Martin, S.; Steiner, D. F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. *J. Biol. Chem.* **1995**, *270* (44), 26488–26496.
- (71) Montminy, M. R.; Sevarino, K. A.; Wagner, J. A. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc. Natl. Acad. Sci. U.S.A.* **1986**, *83* (18), 6682–6686.
- (72) Inceoglu, B.; Schmelzer, K. R.; Morisseau, C.; Jinks, S. L.; Hammock, B. D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). *Prostaglandins Other Lipid Mediators* **2007**, *82* (1–4), 42–49.
- (73) Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapere, J. J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M. R.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. *Trends Pharmacol. Sci.* **2006**, *27* (8), 402–409.
- (74) Papadopoulos, V.; Lecanu, L.; Brown, R. C.; Han, Z.; Yao, Z. X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. *Neuroscience* **2006**, *138* (3), 749–756.
- (75) Stocco, D. M. StAR protein and the regulation of steroid hormone biosynthesis. *Annu. Rev. Physiol.* **2001**, *63*, 193–213.

(76) Wang, X.; Shen, C. L.; Dyson, M. T.; Yin, X.; Schiffer, R. B.; Grammas, P.; Stocco, D. M. The involvement of epoxygenase metabolites of arachidonic acid in cAMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression. *J. Endocrinol.* **2006**, *190* (3), 871–878.

(77) Munos, B. Lessons from 60 years of pharmaceutical innovation. *Nat. Rev. Drug Discov.* **2009**, *8* (12), 959–968.